amiselimod   

GtoPdb Ligand ID: 9319

Synonyms: Example 1 [US20090137530] | MT-1303 | MT1303
Compound class: Synthetic organic
Comment: Amiselimod (MT-1303) is claimed in patent US20090137530 (Compound 1-3 is the hydrochloride used experimentally) as a potential immunomodulatory agent [1]. It is a sphingosine-1-phosphate (SIP) receptor prodrug agonist, similar in action to the approved MS drug fingolimod, but with improved receptor subtype selectivity [3].
Selective SIP1 receptor agonists are being investigated for immunomodulatory/immunosuppresant action in MS and other autoimmune conditions [2].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 13
Topological polar surface area 75.71
Molecular weight 377.22
XLogP 4.17
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Canonical SMILES CCCCCCCOc1ccc(cc1C(F)(F)F)CCC(CO)(CO)N
Isomeric SMILES CCCCCCCOc1ccc(cc1C(F)(F)F)CCC(CO)(CO)N
InChI InChI=1S/C19H30F3NO3/c1-2-3-4-5-6-11-26-17-8-7-15(12-16(17)19(20,21)22)9-10-18(23,13-24)14-25/h7-8,12,24-25H,2-6,9-11,13-14,23H2,1H3
InChI Key JVCPIJKPAKAIIP-UHFFFAOYSA-N
No information available.
Summary of Clinical Use
Amiselimod (MT-1303) has completed Phase 2 dose-finding clinical trials in patients with relapsing-remitting multiple sclerosis (NCT01742052) and moderate to severe chronic plaque psoriasis (NCT01987843). Phase 2 trials in Crohn's disease patients are underway.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01742052 Dose-finding Study of MT-1303 Phase 2 Interventional Mitsubishi Tanabe Pharma Corporation
NCT01987843 Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2 Interventional Mitsubishi Tanabe Pharma Corporation